Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01183897
First received: August 16, 2010
Last updated: October 15, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2015
  Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
No publications provided by Memorial Sloan-Kettering Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):